GeneChem Receives FDA No Objection for Siallac6® Ingredient
GeneChem Inc. has received an acknowledgment letter from the U.S. Food and Drug Administration (FDA) stating no objection to its new food ingredient, Siallac6®.
Biotechnology firm GeneChem Inc. announced it has received an acknowledgment letter from the U.S. Food and Drug Administration (FDA). The letter indicates the FDA has no objection to the company's new food ingredient, Siallac6®, which is 6'-sialyllactose sodium salt.
The ingredient is intended for use in infant and toddler formulas. GeneChem developed Siallac6® in collaboration with REJIMUS, INC.
GeneChem stated that the FDA's response is a significant step in its commercialization strategy. The company specializes in AI-powered enzyme engineering and the development of high-value biomaterials.
Sialyllactose is an oligosaccharide naturally found in human breast milk, believed to support immune system development and gut health. GeneChem aims to provide the food industry with quality ingredients.